RPG Life Sciences Ltd
RPG Life Sciences Q1 FY27: Revenue ₹195.7 Cr, PAT ₹30.8 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on RPG Life Sciences Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] - Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18] - Q1 FY27 PAT: ₹30.8 EBITDA: ₹41.5 crores in Q1 FY27, up 17.0% from ₹35.4 crores in Q1 FY26 - EBITDA Margin: 21.2% in Q1 FY27, slightly up from 21.0% in Q1 FY26 - Revenue from Operations: ₹195.7 crores in Q1
From RPG Life Sciences Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18]
- Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18]
- Q1 FY27 PAT: ₹30.8 crores, up 17.0% YoY (Q1 FY26: ₹26.3 crores) [Page 18]
- Domestic Formulations sales: ₹132.5 crores, up 14.8% YoY (Q1 FY26: ₹115.4 crores) [Page 19]
2 more points management made on revenue & sales performance
Profitability & Margins
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs 185+ crores capex infused since FY22 to build a modern, state-of-the-art plant with approvals from EU, TGA, PMDA, etc. (Page 24)
- Evaluation ongoing for varied opportunities to improve manufacturing productivity (Page 24)
- Ankleshwar multipurpose formulation plant equipped for low humidity products serving domestic and emerging markets; strong production capacity (Page 8)
- API manufacturing facility in Navi Mumbai with three units including a dedicated immunosuppressant unit, catering to regulated markets (Page 8)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
RPG Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹177 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Symbiotec Pharmalab Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
Frequently Asked Questions
What were RPG Life Sciences Ltd Q1 FY27 results?
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] - Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18] - Q1 FY27 PAT: ₹30.8 EBITDA: ₹41.5 crores in Q1 FY27, up 17.0% from ₹35.4 crores in Q1 FY26 - EBITDA Margin: 21.2% in Q1 FY27, slightly up from 21.0% in Q1 FY26 - Revenue from Operations: ₹195.7 crores in Q1
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
Rs 185+ crores capex infused since FY22 to build a modern, state-of-the-art plant with approvals from EU, TGA, PMDA, etc.
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.